Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models

被引：20

作者：

Winter-Holt, Jon J. ^{[2
]}

Bardelle, Catherine ^{[1
]}

Chiarparin, Elisabetta ^{[2
]}

Dale, Ian L. ^{[3
]}

Davey, Paul R. J. ^{[2
]}

Davies, Nichola L. ^{[2
]}

Denz, Christopher ^{[4
]}

Fillery, Shaun M. ^{[2
]}

Guerot, Carine M. ^{[2
]}

Han, Fujin ^{[5
]}

Hughes, Samantha J. ^{[2
]}

Kulkarni, Meghana ^{[4
,6
]}

Liu, Zhaoqun ^{[5
]}

Milbradt, Alexander ^{[3
]}

Moss, Thomas A. ^{[2
]}

Niu, Huijun ^{[5
]}

Patel, Joe ^{[3
,7
]}

Rabow, Alfred A. ^{[2
,8
]}

Schimpl, Marianne ^{[3
]}

Shi, Junjie ^{[5
]}

Sun, Dongqing ^{[5
]}

Yang, Dejian ^{[5
]}

Guichard, Sylvie ^{[4
,9
]}

机构：

[1] AstraZeneca, BioPharmaceut R&D, Macclesfield SK10 4TG, Cheshire, England

[2] AstraZeneca, Oncol, Cambridge CB4 0FZ, England

[3] AstraZeneca, BioPharmaceut R&D, Cambridge CB4 0FZ, England

[4] AstraZeneca, Oncol R&D, Waltham, MA 02451 USA

[5] Pharmaron Beijing Co Ltd, Beijing 100176, Peoples R China

[6] BAKX Therapeut, 551 Mt Guardian Rd Ext,POB 398, Bearsville, NY 12409 USA

[7] Treeline Biosci, 500 Arsenal St, Watertown, MA 02472 USA

[8] 20 Bridge St, Macclesfield SK11 6EG, Cheshire, England

[9] Forma Therapeut, 300 North Beacon St,Suite 501, Watertown, MA 02472 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2022年 / 65卷 / 04期

关键词：

CHEMICAL PROBE; FAMILY; SCALE;

D O I：

10.1021/acs.jmedchem.1c01871

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

ATAD2 is an epigenetic bromodomain-containing target which is overexpressed in many cancers and has been suggested as a potential oncology target. While several small molecule inhibitors have been described in the literature, their cellular activity has proved to be underwhelming. In this work, we describe the identification of a novel series of ATAD2 inhibitors by high throughput screening, confirmation of the bromodomain region as the site of action, and the optimization campaign undertaken to improve the potency, selectivity, and permeability of the initial hit. The result is compound 5 (AZ13824374), a highly potent and selective ATAD2 inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models.

引用

页码：3306 / 3331

页数：26

共 50 条

[21] ODM-207: A novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER plus breast cancer
Moilanen, A.
Lindqvist, J.
Bjorkman, M.
Riikonen, R.
Nicorici, D.
Mattila, E.
Abbineni, C.
Jaleel, M.
Eriksson, J.
Kallio, P.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 5 - 5
[22] Discovery of GH1581, a potent and selective WRN inhibitor as a cancer therapy
Li, Jiapeng
Zhang, Guiping
Li, Jie Jack
[J]. CANCER RESEARCH, 2024, 84 (06)
[23] Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor
Hagihara, Shuichi
Ishizawa, Kouhei
Soga, Kana
Honjo, Takashi
Takai, Shigeki
Kawano, Yuko
Kikuchi, Manami
Nishidate, Akiko
Matsumoto, Fumi
Murase, Mikako
Hashimoto, Naohiro
Sasaki, Chiduko
Miyaguchi, Ikuko
Okada, Okimasa
Akashi, Tomoya
Nakayama, Shinji
Ogasawara, Yuko
Endo, Junichi
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 109
[24] A novel histone deacetylase inhibitor with potent antiproliferative activity in ovarian cancer cells.
Mand, Michael
Edwards, Ceazon
Tumati, Vasu
Kulp, Samuel K.
Chen, Ching-Shih
Nephew, Kenneth P.
Balch, Curtis
[J]. CANCER RESEARCH, 2006, 66 (08)
[25] ARIMIDEX: A potent and selective aromatase inhibitor for the treatment of advanced breast cancer
Buzdar, AU
Jonat, W
Howell, A
Plourde, PV
[J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1997, 61 (3-6): : 145 - 149
[26] Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
Zhang, Zhuming
Ding, Qingjie
Liu, Jin-Jun
Zhang, Jing
Jiang, Nan
Chu, Xin-Jie
Bartkovitz, David
Luk, Kin-Chun
Janson, Cheryl
Tovar, Christian
Filipovic, Zoran M.
Higgins, Brian
Glenn, Kelli
Packman, Kathryn
Vassilev, Lyubomir T.
Graves, Bradford
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (15) : 4001 - 4009
[27] Identification and characterization of a potent and selective HUNK inhibitor for treatment of HER2+breast cancer
Dilday, Tinslee
Abt, Melissa
Ramos-Solis, Nicole
Dayal, Neetu
Larocque, Elizabeth
Oblak, Adrian L.
Sintim, Herman O.
Yeh, Elizabeth S.
[J]. CELL CHEMICAL BIOLOGY, 2024, 31 (05)
[28] Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, James
Lee, John T.
Wang, Weiru
Zhang, Jiazhong
Cho, Hanna
Mamo, Shumeye
Bremer, Ryan
Gillette, Sam
Kong, Jun
Haass, Nikolas K.
Sproesser, Katrin
Li, Ling
Smalley, Keiran S. M.
Fong, Daniel
Zhu, Yong-Liang
Marimuthu, Adhirai
Nguyen, Hoa
Lam, Billy
Liu, Jennifer
Cheung, Ivana
Rice, Julie
Suzuki, Yoshihisa
Luu, Catherine
Settachatgul, Calvin
Shellooe, Rafe
Cantwell, John
Kim, Sung-Hou
Schlessinger, Joseph
Zhang, Kam Y. J.
West, Brian L.
Powell, Ben
Habets, Gaston
Zhang, Chao
Ibrahim, Prabha N.
Hirth, Peter
Artis, Dean R.
Herlyn, Meenhard
Bollag, Gideon
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (08) : 3041 - 3046
[29] Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines
Zhang, Yanmin
Chen, Yadong
Zhang, Danfeng
Wang, Lu
Lu, Tao
Jiao, Yu
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (01) : 140 - 157
[30] Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR
Petros, Andrew M.
Huth, Jeffrey R.
Oost, Thorsten
Park, Cheol-Min
Ding, Hong
Wang, Xilu
Zhang, Haichao
Nimmer, Paul
Mendoza, Renaldo
Sun, Chaohong
Mack, Jamey
Walter, Karl
Dorwin, Sarah
Gramling, Emily
Ladror, Uri
Rosenberg, Saul H.
Elmore, Steven W.
Fesik, Stephen W.
Hajduk, Philip J.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (22) : 6587 - 6591

← 1 2 3 4 5 →